Know Cancer

forgot password

Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations

40 Years
Not Enrolling
Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations



- Compare the systemic exposure of sulindac tablets vs sulindac capsules in healthy


- Compare the terminal half-life and time of peak drug concentration of sulindac tablets
vs sulindac capsules.

OUTLINE: This is a randomized study. Participants are randomized to 1 of 2 treatment arms.

- Arm I: Participants receive one sulindac capsule followed 7-10 days later by one
sulindac tablet.

- Arm II: Participants receive one sulindac tablet followed 7-10 days later by one
sulindac capsule.

Blood is collected periodically during treatment for pharmacokinetic studies.

After completion of study therapy, participants are followed at 7-10 days.

PROJECTED ACCRUAL: A total of 28 participants will be accrued for this study.

Inclusion Criteria


- Healthy volunteer


- ECOG performance status 0-2

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Hemoglobin ≥ 12.0 g/dL (women)

- Hemoglobin ≥ 13.5 g/dL (men)

- WBC > 3,000/mm³

- Platelet count > 100,000/mm³

- Absolute neutrophil count > 1,500/mm³

- Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- ALT ≤ 1.5 times ULN

- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 30 mL/min

- No history of allergic reactions or hypersensitivity to sulindac or other NSAIDs,
including aspirin-sensitive asthma or urticaria

- No condition that interferes with ingestion or absorption of oral medications

- No cancer within the past 3 years except nonmelanomatous skin cancer, localized
prostate cancer, carcinoma in situ of the cervix, or superficial bladder cancer that
was previously treated > 6 months ago

- No uncontrolled concurrent illness including, but not limited to, the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Myocardial infarction in the past 6 months

- Chronic renal disease

- Chronic liver disease

- Hypertension that is difficult to control

- Psychiatric illness or social situations that would limit study compliance

- No other significant clinical disorder or laboratory finding that would preclude
study participation

- No consumption of alcoholic or caffeinated beverages for ≥ 24 hours prior to study
drug administration and until all blood samples have been drawn

- Willing to provide required biologic specimens


- More than 6 months since prior investigational agents

- More than 6 months since prior regular use of (defined as a frequency of 7
consecutive days for > 3 weeks or > 21 days total) or other concurrent nonsteroidal
anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX)-2 inhibitors including, but
not limited to, the following:

- Ibuprofen

- Ketoprofen

- Naproxen

- More than 6 weeks since prior oral corticosteroids

- More than 30 days since prior and no concurrent use of any of the following:

- Methotrexate

- Corticosteroids

- Warfarin

- Ticlopidine

- Clopidogrel

- Low molecular weight heparins

- Abciximab

- Dipyridamole

- Eptifibatide

- Tirofiban

- Lithium

- Cyclosporine

- Hydralazine

- Angiotensin-converting enzymes (ACE) inhibitors

- ACE-receptor antagonists allowed

- Angiotensin-receptor blockers

- Ginkgo

- Ketorolac

- Levofloxacin

- Loop diuretics

- Meadowsweet

- Selective serotonin reuptake inhibitors

- Danaparoid

- No concurrent regular aspirin use unless prescribed by a physician for prevention

- A maximum of one aspirin (81 mg/day) allowed

- No concurrent herbal products (e.g., saw palmetto or Hypericum perforatum [St. John's

Type of Study:


Study Design:

Allocation: Randomized, Primary Purpose: Prevention

Principal Investigator

Paul J. Limburg, MD, MPH

Investigator Role:

Study Chair

Investigator Affiliation:

Mayo Clinic


United States: Federal Government

Study ID:




Start Date:

April 2006

Completion Date:

October 2007

Related Keywords:

  • Unspecified Adult Solid Tumor, Protocol Specific
  • unspecified adult solid tumor, protocol specific



Mayo Clinic Cancer Center Rochester, Minnesota  55905